Source link : https://www.newshealth.biz/health-news/izokibep-enthesitis-benefit-lacking-in-phase-2b-3-psa-trial/
VIENNA — The investigational interleukin (IL)-17 inhibitor izokibep hit its mark when it came to improving overall disease activity in people with active psoriatic arthritis (PsA) in a phase 2b/3 trial, but it was no better than placebo at reducing inflammation of the entheses. This apparent and unexpected lack of effect in the entheses was […]
Author : News Health
Publish date : 2024-06-19 12:18:32
Copyright for syndicated content belongs to the linked Source.
Categories